Goldman Sachs downgraded WuXi Biologics to Neutral from Buy with a price target of HK$21.60, down from HK$50. The firm notes the China CRO/CDMO sector has experienced significant market volatility following the introduction of a draft version of the “BIOSECURE Act” bill in the U.S. House of Representatives on January 25 – and a subsequent, similar bill proposed in the U.S. Senate last week.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on WXIBF: